Drug Metabolism Explained: Phase I and Phase II Reactions

Drug-drug interactions can occur through enzyme induction or inhibition: (1) Enzyme induction - some drugs (e.g., rifampin, phenytoin, carbamazepine) increase CYP450 enzyme activity, accelerating metabolism of other drugs and reducing their effectiveness; (2) Enzyme inhibition - some drugs (e.g., cimetidine, grapefruit juice) decrease CYP450 enzyme activity, slowing metabolism of other drugs and increasing their concentrations. These interactions are clinically significant and must be considered when prescribing multiple drugs.

Drug enzyme interactions affect drug metabolism: (1) Enzyme induction increases metabolic activity, reducing drug concentrations and therapeutic effects (e.g., rifampin, alcohol, carbamazepine, phenytoin, St. John's wort), (2) Enzyme inhibition decreases metabolic activity, increasing drug concentrations and potentially causing toxicity (e.g., grapefruit juice, erythromycin, cimetidine, fluconazole, acute alcohol consumption). These interactions are clinically significant, especially for drugs with narrow therapeutic indices.

Drug interactions occur through enzyme inhibition (blocking active sites, causing immediate toxicity) or induction (increasing enzyme production, causing delayed underdosing). MAO inhibitors were discovered accidentally when tuberculosis patients showed improved mood; these drugs covalently inhibit MAO enzymes that normally break down neurotransmitters. The 'cheese syndrome' occurs because fermented foods contain tyramine, which normally gets metabolized by gut MAO - without MAO activity, tyramine enters systemic circulation and causes dangerous hypertension. Grapefruit juice contains furanocoumarins that inhibit CYP3A4, increasing drug concentrations. Rifampicin induces CYP enzymes, decreasing drug effectiveness. Birth control pills can be rendered ineffective by St. John's Wort. Understanding these interactions requires knowing a drug's metabolic pathway. This explains why prescribing guidelines warn about combining certain medications and why patients should inform healthcare providers about all substances they consume.

Enzyme inhibition occurs when one drug slows down the metabolic enzymes, increasing the blood levels of other drugs. Enzyme induction occurs when one drug speeds up metabolic enzymes, decreasing the blood levels of other drugs. For example, grapefruit juice inhibits CYP3A4 enzymes, increasing levels of many drugs. Conversely, rifampin induces these enzymes, decreasing levels of many drugs.

Enzyme induction increases metabolic enzyme activity, reducing drug concentrations and effectiveness. Examples include rifampin (induces many enzymes, reducing oral contraceptive effectiveness) and chronic alcohol use (induces alcohol-metabolizing enzymes). Enzyme inhibition decreases metabolic enzyme activity, increasing drug concentrations and potential toxicity. Examples include fluoxetine (inhibits CYP2D6) and grapefruit juice (inhibits intestinal CYP3A4). These interactions require careful monitoring and dose adjustments.

Acetaminophen is metabolized primarily by conjugation, but a small portion forms NAPQI, a toxic metabolite normally detoxified by glutathione. In overdose or with depleted glutathione (chronic alcohol users), NAPQI accumulates causing hepatotoxicity. Treatment includes N-acetylcysteine (replenishes glutathione), methionine, and activated charcoal. Acetaminophen is particularly dangerous in children due to palatable formulations. This is a critical consideration in pediatric medicine.

Acetaminophen metabolism occurs primarily through glucuronidation (60%) and sulfation (30%), with a small portion metabolized by CYP2E1 to form NAPQI (N-acetyl-p-benzoquinone imine). Under normal circumstances, NAPQI is detoxified by glutathione, but in overdose situations, NAPQI accumulates and causes hepatocellular necrosis. Alcohol consumption induces CYP2E1 enzyme activity, increasing NAPQI formation and hepatotoxicity risk even at therapeutic doses. This explains why patients consuming alcohol are at higher risk for acetaminophen-induced liver damage. Unlike some drugs with unknown hepatotoxicity mechanisms, acetaminophen's toxicity is directly linked to NAPQI accumulation, enabling development of antidotes like N-acetylcysteine.

Under normal conditions, NAPQI is quickly converted into non-toxic paracetamol glutathione by binding with glutathione. During overdose, the first two metabolic pathways become overwhelmed and cannot process all incoming paracetamol. Excess paracetamol is rerouted to the third pathway, which normally produces only 15% of metabolites. This causes massive spike in NAPQI production. The liver's glutathione stores are quickly depleted because this pathway is not normally used to this extent, leading to toxic NAPQI accumulation.

When acetaminophen is broken down in the liver, one key metabolite produced is N-acetyl-p-benzoquinone imine (NAPQI), a toxic compound. Normally, the body uses glutathione, a critical antioxidant molecule, to neutralize NAPQI. However, when excessive acetaminophen is taken over time or in susceptible individuals (such as older adults whose glutathione levels decline with age), glutathione stores become depleted, leading to NAPQI accumulation and cellular damage.

Paracetamol overdose causes severe hepatotoxicity through the formation of NAPQI (N-acetyl-p-benzoquinone imine), a toxic metabolite. Risk factors for severe hepatotoxicity include chronic alcohol consumption (which depletes glutathione stores) and malnutrition (which also reduces glutathione). NAPQI directly damages hepatocytes, and when glutathione is depleted, the toxic metabolite accumulates and causes liver damage. The antidote is N-acetylcysteine, which replenishes glutathione stores.

First pass metabolism describes drug metabolism occurring before reaching systemic circulation. The liver's dual blood supply enables this: drugs absorbed from the GI tract travel via the portal vein to the liver, where they are metabolized before entering general circulation. Oral and rectal administration routes undergo first pass metabolism, while sublingual and intramuscular routes bypass it. Bioavailability—the fraction of drug reaching systemic circulation—directly reflects first pass extent. Drugs with low bioavailability indicate significant hepatic metabolism. Additionally, intestinal enzymes contribute to pre-systemic metabolism, further reducing drug availability.

When drugs are taken orally, they pass through the liver first before reaching systemic circulation. This first-pass metabolism significantly reduces bioavailability, meaning only a fraction of the administered dose reaches the bloodstream. For example, if 100mg of drug is taken orally, only about 60mg may reach the body due to hepatic metabolism. This is why some drugs are administered via alternative routes (IV, transdermal) to bypass first-pass metabolism. Natural estrogens are not given orally in oral contraceptives because they undergo extensive first-pass metabolism, resulting in very low bioavailability. Instead, synthetic estrogens are used which have higher bioavailability and are more effective for contraception.

First-pass metabolism refers to hepatic metabolism of orally administered drugs before reaching systemic circulation. After absorption through the gastrointestinal tract, drugs enter the hepatic portal system and pass through the liver, where a portion is metabolized (often rendered inactive) before systemic distribution. This process dramatically reduces bioavailability - for example, nitroglycerin undergoes extensive first-pass metabolism, with only about 10% of an oral dose reaching systemic circulation compared to nearly 100% with IV administration. Drugs with significant first-pass metabolism (like propranolol, morphine, and many others) achieve poor systemic concentrations when given orally, necessitating alternative routes of administration. Sublingual, buccal, rectal, intravenous, intramuscular, and subcutaneous routes bypass hepatic first-pass metabolism, making them preferable for these drugs.

First pass metabolism (first pass effect) is the process where drugs get metabolized as they pass through the body before reaching their site of action, primarily occurring in the liver but also involving the gastrointestinal tract and lungs; this reduces drug concentration at the site of action and has significant clinical implications including genetic polymorphism affecting enzyme levels (creating hyper-metabolizers and poor-metabolizers), route of administration affecting bioavailability (IV > transdermal > injectables > suppositories > oral), and special considerations for prodrugs which become active only after metabolism.

First-pass metabolism occurs when drugs pass through the liver before reaching systemic circulation, reducing effectiveness. Bioavailability is the percentage of drug reaching circulation unchanged. Order of first-pass metabolism (highest to lowest): Oral > Rectal > Parenteral (IV, IM, SC). Order of bioavailability (lowest to highest): Oral < Rectal < Parenteral. Sublingual, intranasal, and inhalation routes also provide 100% bioavailability by bypassing the liver.

For oral drugs, hepatic metabolism is the primary clearance pathway because oral drugs are typically non-polar and membrane-permeable, allowing them to undergo tubular reabsorption in the kidneys and thus have low renal clearance; however, once drugs are metabolized into more polar phase II metabolites (such as those conjugated with sulfate or glutathione), these metabolites become less membrane-permeable and are preferentially excreted via renal and biliary pathways, making hepatic clearance the main factor for parent drug elimination while other pathways primarily affect metabolites.

Drug excretion occurs primarily through kidneys (urine) and bile (stool). Renal excretion involves three mechanisms: glomerular filtration (requires free, unbound drug), active tubular secretion (via organic ion transporters), and passive tubular reabsorption (uncharged lipid-soluble molecules cross membranes). Ion trapping occurs when weak acids/bases are converted to charged forms by urine pH manipulation—alkalinization increases weak acid excretion, acidification increases weak base excretion. Biliary excretion involves conjugated drugs (Phase II products) secreted in bile, with enterohepatic cycling allowing reabsorption from intestines.

Phase II metabolism uses conjugation reactions to dramatically increase drug polarity for excretion. UDP-glucuronosyltransferase adds glucuronic acid, glutathione S-transferase adds glutathione, sulfotransferase adds sulfate, and acetyltansferase adds acetyl groups. These reactions transform hydrophobic drugs into highly polar molecules suitable for elimination via urine, bile, or blood distribution. Deficiencies in these enzymes cause severe conditions like Crigler-Najjar syndrome and gray baby syndrome.

Drug metabolism occurs in two phases: Phase I (catabolic) involves cytochrome P450-catalyzed oxidation, reduction, and hydrolysis; Phase II (anabolic) involves conjugation reactions adding polar groups. Metabolites may be active or inactive. The kidney is the primary excretion organ, where lipophilic drugs are reabsorbed while hydrophilic metabolites are excreted. Ionization state affects reabsorption: non-ionized forms are more lipophilic and better reabsorbed. This explains why urinary pH manipulation affects elimination rates.

Drug metabolism serves to increase polarity for renal elimination. Phase I reactions (oxidation, reduction, hydrolysis) modify drug structure, while Phase II reactions (glucuronidation, sulfation) conjugate polar groups. Drugs too large or lipophilic for renal excretion are eliminated via biliary route (feces). Only the free (unbound) drug fraction is pharmacologically active, as bound drug is attached to plasma proteins like albumin.